Evidence map›Paper›PMID 38126310›Full record

ArticleACS nano2024

Balancing the Nanoscale Organization in Multivalent Materials for Functional Inhibition of the Programmed Death-1 Immune Checkpoint.

Kaltrina Paloja, Jorieke Weiden, Joschka Hellmeier, Alexandra S Eklund, Susanne C M Reinhardt, Ian A Parish, Ralf Jungmann, Maartje M C Bastings

Open access · hybridAbstract read
In one paragraph

Article in ACS nano, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
4.1field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 25 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Review
  15. Fluidic Interface for Surface-based DNA Origami Studies.ACS applied materials & interfaces · 2024
    Article
  16. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 3 countries.

Kaltrina PalojaProgrammable Biomaterials Laboratory, Institute of Materials, School of Engineering, École Polytechnique Fédérale de Lausanne, Lausanne 1015, Switzerland.ORCID 0000-0001-8504-9919
Jorieke WeidenProgrammable Biomaterials Laboratory, Institute of Materials, School of Engineering, École Polytechnique Fédérale de Lausanne, Lausanne 1015, Switzerland.ORCID 0000-0002-2485-0590
Joschka HellmeierMax Planck Institute of Biochemistry, Planegg 82152, Germany.ORCID 0000-0002-7153-9121
Alexandra S EklundMax Planck Institute of Biochemistry, Planegg 82152, Germany.ORCID 0000-0003-1047-2100
Susanne C M ReinhardtMax Planck Institute of Biochemistry, Planegg 82152, Germany.ORCID 0000-0003-0177-4801
Ian A ParishPeter MacCallum Cancer Centre, Melbourne, VIC 3000, Australia.
Ralf JungmannMax Planck Institute of Biochemistry, Planegg 82152, Germany.ORCID 0000-0003-4607-3312
Maartje M C BastingsProgrammable Biomaterials Laboratory, Institute of Materials, School of Engineering, École Polytechnique Fédérale de Lausanne, Lausanne 1015, Switzerland.ORCID 0000-0002-7603-4018
École Polytechnique Fédérale de Lausanne · CHCenter for NanoScience · DEMax Planck Institute of Biochemistry · DEThe University of Melbourne · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Dendritic cells (DCs) regulate immune priming by expressing programmed death ligand 1 (PD-L1) and PD-L2, which interact with the inhibitory receptor PD-1 on activated T cells. PD-1 signaling regulates T cell effector functions and limits autoimmunity. Tumor cells can hijack this pathway by overexpressing PD-L1 to suppress antitumor T cell responses. Blocking this inhibitory pathway has been beneficial for the treatment of various cancer types, although only a subset of patients responds. A deepened understanding of the spatial organization and molecular interplay between PD-1 and its ligands may inform the design of more efficacious nanotherapeutics. We visualized the natural molecular PD-L1 organization on DCs by DNA-PAINT microscopy and created a template to engineer DNA-based nanoclusters presenting PD-1 at defined valencies, distances, and patterns. These multivalent nanomaterials were examined for their cellular binding and blocking ability. Our data show that PD-1 nano-organization has profound effects on ligand interaction and that the valency of PD-1 molecules modulates the effectiveness in restoring T cell function. This work highlights the power of spatially controlled functional materials to unravel the importance of multivalent patterns in the PD-1 pathway and presents alternative design strategies for immune-engineering.

Indexed as

B7-H1 AntigenNeoplasmsDNAHumansProgrammed Cell Death 1 ReceptorT-LymphocytesB7-H1 AntigenDNAProgrammed Cell Death 1 Receptordendritic cellsDNA origamiimmune checkpoint blockademultivalencyPD-1spatial organizationT cell activation

Identifiers

PMID38126310
PMCPMC10795474
OpenAlexW4390059340

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.